A stage two resource alert has been issued jointly by NHS Improvement and the Medicines and Healthcare products Regulatory Agency (MHRA) to support the safety of girls and women of childbearing potential being treated with valproate.
The MHRA has updated its valproate toolkit, providing a range of resources to support providers, staff and patients in the safe use of valproate.
This alert asks all providers to undertake systematic identification of girls and women who are taking valproate, and to ensure the MHRA resources are used to support them to make informed choices.
The RPS has produced guidance for dispensing valproate for girls and women.
Further details of the alert and action to take can be found on the NHS Improvement website.